Anti-Cancer Drugs Acalabrutinib: Hoʻomaʻamaʻa No CLL / SLL / MCL - AASraw
Hana ʻo AASraw i ka paukū Cannabidiol (CBD) a me ka Hemp Essential Oil i ka nui!

ʻO nā lāʻau lapaʻau anti-cancer Acalabrutinib

 

  1. ʻO Acalabrutinib Backgroud
  2. ʻO nā loiloi Acalabrutinib
  3. Acalabrutinib iapaau ana (hoʻohana no)
  4. Ka Hana Hana Acalabrutinib
  5. He aha nā hopena ʻē aʻe o Acalabrutinib?
  6. ʻO Acalabrutinib VS Ibrutinib
  7. ʻImi: Acalabrutinib Ma ka mālama ʻana i ka leukemia lymphocytic maʻi (CLL)

 

ʻO Acalabrutinib Backgroud

I kēia lā, ua hoʻohana ʻia ka acalabrutinib i nā hoʻokolohua e aʻo ana i ka mālama ʻana o B-All, Myelofibrosis, Ovarian Cancer, Multel Myeloma, a me Hodgkin Lymphoma, a me nā mea ʻē aʻe ʻē aʻe.

Ma ka lā ʻOkakopa 31, 2017 ua ʻae ʻo FDA i kā Calgerence waha ʻole o Astra Zeneca (acalabrutinib). Hōʻike kēia mea hoʻopuka Bruton Tyrosine Kinase (BTK) no ka mālama ʻana i ka leukemia lymphocytic mau, lympoma liʻiliʻi lymphocytic, a me nā mea maʻi me Mantle Cell Lymphoma (MCL) i loaʻa ma ka liʻiliʻi he hoʻokahi ma mua o ka lāʻau.

Ua'ike pū'ia ACP-196, acalabrutinib ka mea i manaʻo ʻia he ʻoki hanauna BTK ʻelua no ka mea ua hoʻolālā kūpono ʻia e ʻoi aku ka ikaika a me ke koho ma mua o ka ibrutinib, manaʻo ʻia e hōʻike i ka hopena o nā hopena ʻino e pili ana i nā hopena i hōʻemi ʻia e nā hopena ma nā pahuhopu ʻē aʻe o BTK.

Eia nō naʻe, ʻae ʻia ka acalabrutinib ma lalo o ke ala ʻae wikiwiki a ka FDA, i hoʻokumu ʻia ma luna o ka pane pane laulā a me nā limahana i ka ʻae mua ʻana o nā lāʻau lapaʻau e mālama ana i nā kūlana koʻikoʻi a i ʻole e hoʻopiha ana i kahi pono olakino pono ʻole ʻia e pili ana i kahi hopena hope. ʻO ka ʻae ʻia no ka acalabrutinib mau mea i ʻae ʻia i kēia manawa e pili ana i ka hōʻoia mau a me ka wehewehe ʻana o ka pōmaikaʻi lapaʻau i nā hoʻokolokolo confimatory.

Eia kekahi, ua hāʻawi ka FDA i kēia lāʻau lapaʻau Priority Review a me Breakthrough Therapy inoa. Ua loaʻa iā ia ka inoa ʻo Orphan Drug, e hāʻawi ana i nā mea hoʻoikaika e kōkua a paipai i ka hoʻomohala ʻana i nā lāʻau no nā maʻi laha ʻole. I kēia manawa, ʻoi aku ma mua o 35 mau hoʻokolohua hoʻokolohua ma nā ʻāina he 40 a ʻoi aku ma mua o 2500 mau maʻi e holo nei a i ʻole ua hoʻopau ʻia e pili ana i ka noiʻi hou ʻana i ka ʻike maikaʻi a me ka hoʻonui ʻana i nā hoʻohana therapeutic o acalabrutinib 5.

 

ʻO Acalabrutinib Reviews

Acalabrutinib (CAS:1420477-60-6), ka mea i kūʻai ʻia ma lalo o ka tradename o Calquence® i ka US a me Kanada, he hanauna ʻelua mole kūpili liʻiliʻi o kā Bruton's tyrosine kinase (BTK). Ma ka hoʻoponopono waha, hoʻopaʻa paʻa ʻo acalabrutinib i ka hana a BTK e pale ai i ka hoʻāʻo B-cell a me ka hōʻailona waena waena o B-cell. Ke alakaʻi nei kēia hana i ka pāpā ʻana i ka ulu ʻana o nā keena B ʻinoʻino e overexpress BTK. Koi ʻia ʻo BTK no ka hōʻailona B-cell, he kuleana nui i ka ulu ʻana o ka pūnaewele B, a ua hōʻike ʻia i loko o kahi mau maʻi maʻi B-cell, me CLL / SLL. Pili ka ʻōlelo o BTK i nā hunaola tumele me ka hoʻonui ʻia o ka hoʻonui a me ke ola. Ma ke ʻano he mea kāohi BTK hanauna ʻelua, ua hoʻolālā ʻia ʻo acalabrutinib e hoʻonui i ka hopena ma BTK a hoʻēmi i ka hana i waho o ka pahuhopu ma TEC (Tec Protein Tyrosine Kinase), EGFR (receptor mea ulu ulu epidermal), a me ITK (interleukin-2-inducible T- kinase pūnaewele). ʻO ka hanauna BTK hanauna mua, ibrutinib (Imbruvica), nele i kēia kikoʻī e hopena ai i nā hopena kiʻekiʻe aʻe o nā hopena maikaʻi ʻole. Ma waho o CLL / SLL, ʻae ʻia acalabrutinib no Mantle Cell Lymphoma (MCL). ʻO ka papa kuhikuhi National Cancer Center Network (NCCN) papa kuhikuhi acalabrutinib me a i ʻole obinituzumab i laina mua no CLL / SLL a kūpono hoʻi no ka hoʻohana ʻana i CLL relapsed a refactory (R / R) hoʻi.

 

ʻO Acalabrutinib Lapaʻau (Hoʻohana ʻia no)

Hoʻohana ʻia ʻo Acalabrutinib e mālama i ka poʻe me ka limle cell lymphoma (MCL; kahi kanesa ulu ulu e hoʻomaka ana i nā hunaola o ka ʻōnaehana pale) i mālama ʻia me hoʻokahi lāʻau chemotherapy ʻē aʻe.

Hoʻohana wale ʻia ʻo Acalabrutinib a i ʻole me obinutuzumab (Gazyva) e mālama ai leukemia lymphocytic paleka (CLL; kahi ʻano o ka maʻi ʻaʻai e hoʻomaka i nā hunaola keokeo) a me ka lymphocytic lymphoma liʻiliʻi (SLL: kahi ʻano o Ka maʻi 'aʻai e hoʻomaka i nā keokeo o ke koko).

Aia ʻo Acalabrutinib i ka papa o nā lāʻau i kapa ʻia nā kinase inhibitors. Hana ia ma ke kāpae ʻana i ka hana o ka protein pono ʻole e hōʻailona ai i nā hunaola maʻi ʻaʻai e hoʻonui. Mālama kēia i ka laha ʻana o nā hunaola maʻi ʻaʻai.

 

ʻO Acalabrutinib Hana Of Ahoʻoholo

ʻO Mantle Cell Lymphoma (MCL) kahi ʻano laha ʻole akā ʻano kolohe o ka B-cell non-Hodgkin lymphoma (NHL) me ka wānana maikaʻi ʻole. A laila, maʻa mau ka hoʻi hou i nā mea maʻi MCL a hōʻike hope i ka holomua o ka maʻi.

Hana ʻia ʻo Lymphoma ke ulu a ulu a hoʻomāhuahua ʻole ʻia nā limahana lymphocytes. Hiki ke hele i kēlā mau lymphocytes maʻi maʻi i nā ʻāpana he nui o ke kino, e like me nā lymph node, spleen, iwi iwi, ke koko, a me nā mea ʻē aʻe kahi e hiki ai ke hoʻonui a hana i kahi nuipa (es) i kapa ʻia he tumo ʻO kekahi o nā ʻano nui o nā lymphocytes i hiki ke hoʻomohala i nā lymphomas maʻi ʻaʻai, ʻo ia nā B-lymphocytes ponoʻī o ke kino (B-cells).

ʻO Bruton Tyrosine Kinase (BTK) kahi mole mole hōʻailona o ka B-cell antigen receptor a me nā ala receptor cytokine. ʻO ia mau hōʻailona BTK ke kumu o ka hoʻoulu ʻia o nā ala pono e pono ai no ka hoʻonui ʻana o ka cell B, ke kālepa ʻana, ka chemotaxis, a me ke adhesion.

ʻO Acalabrutinib kahi mea mole mole mole mole o BTK. ʻO acalabrutinib ʻelua a me kāna metabolite hana, ACP-5862, hana e hana i kahi paʻa covalent me kahi koena cysteine ​​(Cys481) i ka pūnaewele hana BTK, e alakaʻi ana i ka pāpā ʻana i ka hana enzymatic BTK. nā protein protein CD86 a me CD69, kahi e kāohi ai i ka hoʻolaha B-cell malignant a me ke ola.

ʻOiai ʻo ibrutinib ka mea ʻike ʻia ma ke ʻano he mea kāohi BTK papa mua, ua manaʻo ʻia ʻo acalabrutinib he mea hōʻoki BTK hanauna ʻelua no ka mea hōʻike ia i ka selectivity kiʻekiʻe a me ka pāpā ʻana o ka hana i hoʻomāka ʻia o BTK ʻoiai he IC50 ʻoi aku ka nui a i ʻole aʻaʻohe ʻano kūʻē i ka nā hana kinase o ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, a me YES1.

I ka hopena, hoʻolālā ʻia ʻo acalabrutinib e ʻoi aku ka ikaika a me ke koho ma mua o ka ibrutinib, i nā manawa āpau e hōʻike ana i nā hopena maikaʻi ʻole - i ke kumumanaʻo - no ka hoʻoliʻiliʻi o nā hopena i hopena ʻia i ka lāʻau.

ʻO AASraw ka mea hana ʻoihana o Acalabrutinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

He aha nā hopena ʻē aʻe o Acalabrutinib?

Hoʻokumu paha ʻo Acalabrutinib i nā hopena ʻē aʻe, e like me:

Hiki i nā maʻi ʻino ke kū i ka wā o ka mālama ʻana me Acalabrutinib a hiki i ka make. Kākau paha kāu mea mālama ola i kekahi mau lāʻau inā loaʻa ka nui o ka makaʻu i ka loaʻa ʻana o nā maʻi. E haʻi koke aku i kāu kauka inā loaʻa iā ʻoe nā hōʻailona a hōʻailona paha o kahi maʻi, e like me ke kuni, ke anuanu, a me nā hōʻailona like flu.

Hiki i nā pilikia kahe ʻana (hemorrhage) ke hana ʻia me ka Acalabrutinib a hiki ke koʻikoʻi a hiki i ka make. E hoʻonui paha kou makaʻu i ke kahe ʻana inā e lawe pū ʻoe i kahi lāʻau ʻoi aku ka momona o ke koko. E haʻi i kāu kauka inā loaʻa iā ʻoe nā hōʻailona a me nā hōʻailona o ke kahe ʻana o ke koko, e like me ke koko i loko o kāu pahu noho a i ʻole nā ​​noho ʻeleʻele (e like me ke tar), mimi a ʻeleʻele ʻeleʻele, kahe koko ʻole ʻia a i ʻole ke kahe ʻana he koʻikoʻi a ʻaʻole hiki ʻole iā ʻoe ke kaohi, ka luaʻi i ke koko a i ʻole ka luaʻi. ke nānā aku e like me ka papa kope, ʻūlū i ke koko a i ʻole ke koko, puʻupuʻu, nāwaliwali, huikau, nā loli i kāu kamaʻilio ʻana, ʻeha ke poʻo i lōʻihi loa, a ʻeha a ʻulaʻula a poni paha i nā ʻili ʻili.

Hoʻoemi i ka helu o ke kahe o ke koko. Hoʻoemi ʻia nā helu o ke koko (nā keʻokeʻo koko keʻokeʻo, nā platelet, a me nā ʻulaʻula o ke koko) i maʻamau me Acalabrutinib, akā hiki nō hoʻi ke koʻikoʻi. Pono kāu mea mālama ola e hana i nā hoʻokolohua koko e nānā i ka helu ʻana o kou koko i ka wā o ka mālama ʻana me Acalabrutinib.

ʻO nā maʻi maʻi maʻi ʻelua. Ua hiki mai nā maʻi ʻino hou i ka poʻe i ka wā o ka mālama ʻana me Acalabrutinib, e like me nā maʻi ʻeha o ka ʻili a i ʻole nā ​​mea ʻē aʻe. E nānā aku kāu mea mālama ola iā ʻoe no nā maʻi ʻili ʻili i ka wā o ka mālama ʻana me Acalabrutinib. E hoʻohana i ka pale o ka lā ke waho ʻoe i ka lā.

Ua loaʻa nā pilikia o ka puʻuwai puʻuwai (atrial fibrillation a me atrial flutter) i ka poʻe i mālama ʻia me Acalabrutinib. E haʻi i kāu kauka inā loaʻa iā ʻoe kekahi o nā hōʻailona aʻe a i ʻole nā ​​hōʻailona: ka wikiwiki a me ke kaulike ʻole o ka puʻuwai, ka paupauaho, ka nāwaliwali, ka ʻoluʻolu o ka umauma, a me ka liʻiliʻi o ka hanu

ʻO nā hopena ʻaoʻao maʻamau o Acalabrutinib me ka ʻeha o ke poʻo, ka maʻi pākī, ka ʻeha a me ka ʻeha pū, ka maʻi hanu o ka hanu luna, a me ka palapū.

ʻAʻole kēia nā hopena āpau o Acalabrutinib. Kāhea i kāu kauka no ka ʻōlelo aʻoaʻo olakino e pili ana i nā hopena. Hiki paha iā ʻoe ke hōʻike i nā hopena i FDA ma 1-800-FDA-1088.

 

ʻO Acalabrutinib

 

 

ʻO Acalabrutinib VS Ibrutinib

He kī nui ʻo BTK i ke ala hōʻailona hōʻailona B-cell; Hoʻopili paʻa ʻole ʻo acalabrutinib iā BTK a kāpae i kāna hana. Ua hoʻolālā ʻia ka lāʻau lapaʻau ma ke ʻano he mea ʻoi aku ka mea hiki ke kāohi iā BTK, i ka hoʻāʻo e hoʻoliʻiliʻi i kekahi o nā lāʻau lapaʻau palena palena ʻana i ʻike pinepine ʻia me ibrutinib. Wahi a Dr. Brown, "ʻO Acalabrutinib ka BTK mea kāohi i ke koho no nā poʻe me nā comorbidities, nā pilikia puʻuwai."

ʻIke like ka ʻikepili efficacy ma waena o acalabrutinib a me ibrutinib, ʻoiai ʻoi aku ka lōʻihi o ka ukali ʻana me ibrutinib, hoʻomau ʻo Dr. No laila, aia ka ʻokoʻa nui ma waena o nā lāʻau i kā lākou ʻaoʻao ʻaoʻao hopena. Hoʻomaʻamaʻa maikaʻi ʻia ʻo Ibrutinib i nā mea maʻi ʻelemakule a pili i nā helu kiʻekiʻe o ka atrial fibrillation a me ke kiʻekiʻe. "ʻOi aku ka maikaʻi o ka hoʻomanawanui ʻana o Acalabrutinib [ma mua o ka ibrutinib], no laila hoʻohana wau ia mea i keu, ʻo ia hoʻi i kaʻu mau mea maʻi ʻelemakule," i ʻōlelo ʻo ia.

ʻO ka ʻae ʻia o ka lāʻau i CLL, i hāʻawi ʻia i Nowemapa 2019, ua hoʻokumu ʻia ma ka ʻikepili palekana a me ka pono mai nā anamanaʻo kūloko o ka hoʻokolokolo ʻana o ELEVATE-TN o nā mea maʻi me CLL i hoʻomaʻamaʻa ʻole ʻole ʻia a me ka hoʻokolokolo ASCEND o nā mea maʻi me CLL relacted a refactory paha. I nā hoʻāʻo ʻelua, acalabrutinib hōʻike i ke ola holomua ʻole kiʻekiʻe kiʻekiʻe i hoʻohālikelike ʻia me ka standard therapy, a me kahi ʻikepili hoʻomanawanui maikaʻi. I ka hoʻokolokolo ʻana iā ELEVATE-TN, kikoʻī, ʻo acalabrutinib i hui pū ʻia me obinutuzumab a me ka monotherapy e hoʻemi ana i ka makaʻu o ka maʻi i ka holomua a i ʻole ka make e 90% a me 80%.

"Ke waiho nei kahi ahonui i kahi pilikia i loko o ka mālama lapaʻau o CLL i kēia manawa, a he pono paha ia e hoʻomau i ka hoʻomaʻamaʻa no nā makahiki he nui," wahi a Jeff Sharman, MD, Luna Hoʻokele o ka noiʻi ma Willamette Valley. Cancer Institute, Luna Hoʻokele Lapaʻau o Hematology Research no The US Oncology Network, a me ka mea kākau nui o ka hoʻokolokolo ʻana ʻo ELEVATE-TN, i kahi hoʻokuʻu nūpepa. "I nā hoʻokolohua ʻo ELEVATE-TN a me ASCEND e hoʻohālikelike ana i ka [acalabrutinib] i nā loiloi hoʻohana maʻamau, ua hōʻike ʻo [acalabrutinib] i kahi hoʻomaikaʻi kūpono i ke ola me ka manuahi o ka holomua i nā mea maʻi ma nā wahi he nui, ʻoiai e hoʻomau ana i ka hoʻomanawanui maikaʻi a me ka ʻike palekana."

 

Huli: ʻO Acalabrutinib Ma ka mālama ʻana Leukemia lymphocytic kiropoli (CLL)  

(1) Leukemia lymphocytic kiropoli (CLL)

ʻO ka maʻi leukemia lymphocytic (CLL), ka leukemia mākua maʻamau, he neoplasm clonal i haku ʻia i nā huna B liʻiliʻi liʻiliʻi e noho pū ana me CD5 a me CD23. Ua loli ka ʻāina o ka lapaʻau ʻana o CLL i nā makahiki i hala iho nei. ʻO nā lāʻau e kuhikuhi ana i nā protein i loko o ka B cell antigen receptor (BCR) pathway, e like me ibrutinib, ua hōʻike i ka hoʻomaikaʻi i ka holomua a me ke ola holoʻokoʻa, e like me nā mea maʻi me nā maʻi kūpilikiʻi nui. ʻOiai ua hoʻohuli kēia mau lāʻau i ka paradigm lapaʻau i nā maʻi me CLL, hiki ke kaupalena ʻia ka mālama ʻana a me ka ikaika me ibrutinib ma muli o ka ʻaoʻao a me ka hopena e pili ana i ka lāʻau lapaʻau. ʻO Acalabrutinib, kahi hanauna ʻelua a ʻoi aku ka mea koho ʻo Tyrosine kinase (BTK) ʻo Bruton, i hoʻomohala ʻia e hoʻonui i ka pono me ka hoʻoliʻiliʻi ʻana i nā hanana kūlike i pili i ka ibrutinib i kuhi ʻia e lilo i kekona i nā hopena kūʻē ʻole o ibrutinib. E hōʻuluʻulu kēia loiloi i ka hoʻomohala, loiloi mua loiloi, a me nā hoʻokolohua hoʻokolohua koʻikoʻi i hōʻike i ka pono o acalabrutinib a me ka hiʻona ʻona ma CLL.

 

(2) Nānā Preclinical o Acalabrutinib ma CLL

Ua hōʻike ʻia kekahi mau noiʻi preclinical i ka hopena o ka acalabrutinib ma ka hopena ʻo BTK. Ke hoʻāʻo ʻia i ke koko holoʻokoʻa o ke kanaka, ua loaʻa i ka acalabrutinib ka pāpā ʻoi aku o ka hana ʻoiaʻiʻo BTK ke hoʻohālikelike ʻia me ibrutinib. Ua loaʻa ʻo Ibrutinib i mea e hoʻonui ai i ka apoptosis o nā hunaʻi CLL ke hoʻohālikelike ʻia me acalabrutinib, i hiki ke wehewehe ʻia e nā hopena pahuhopu ʻole o ibrutinib. ʻAʻohe o ka hopena o Acalabrutinib i nā pūnaewele T olakino ma muli o kāna koho ʻana i hoʻohālikelike ʻia me ibrutinib.

Ua loiloi ʻia nā hopena anti-tumole o acalabrutinib i ʻelua mau hiʻohiʻona CLL murine: kahi hoʻohālikelike hoʻoili lawe hānai a TCL1 a me kahi hiʻohiʻona CLL kanaka xenografted. Ua hōʻike ʻia ʻo Acalabrutinib e kāohi i ka hōʻailona BCR a me ka lapaʻau ʻana me ka acalabrutinib e pili ana me kahi piʻi nui o ke ola ke hoʻohālikelike ʻia me nā ʻiole i hana ʻole ʻia (median 81 mau lā vs 59 mau lā, p = 0.02). Hoʻokumu pū ʻo Acalabrutinib i kahi hōʻemi nui o nā cell proliferating a me ka nui o ke kaumaha o ka tumora i loko o ka māpala.

Ua loiloi ʻia ka pilina o Acalabrutinib me anti-CD20 monoclonal antodies. Hiki paha iā Ibrutinib ke hoʻopilikia i kekahi o nā ʻano hana o ka anti-CD20 antibodies kikoʻī e kāohi ana i ka cytotoxicity cellular-dependant cellular a me ka phagositosis e hoʻoliʻiliʻi ai i kā lākou hopena anti-tumor. a ʻike ʻaʻole ia i hoʻopilikia i kēia mau kaʻina hana, no ka hopena liʻiliʻi o ka hopena o acalabrutinib. ʻOiai ʻo ka hui pū ʻana o ka acalabrutinib me kahi anti-CD20 monoclonal antibody ʻaʻole i aʻo ʻia i kahi hiʻohiʻona in vivo, kekahi mau manawa 2 a me ka pae. Ke hoʻomau nei a 3 paha nā ʻike e hōʻike ana i ka pono o ka acalabrutinib i hui pū ʻia me kahi anti-CD20 monoclonal antibody.

Ua aʻo ʻia nā hui acalabrutinib ʻē aʻe i nā ʻano in vitro a me in vivo. Hoʻohui ʻia ʻo Acalabrutinib me kahi PI3Kdelta mea kāohi (ACP-319) i kahi mole CLL murine a hōʻike i ka hoʻemi nui ʻana o ka ulu ʻana o ka tumora, nā hōʻailona NF-KB a me ka hōʻike ʻana o BCL-xL a me MCL-1 i hoʻohālikelike ʻia me ka monotherapy. ʻaʻole i kākau inoa ʻia i ka hoʻokolokolo hoʻokolohua i mālama ʻia me acalabrutinib a me venetoclax. Ua hōʻike ʻia kēia hui ʻana e hoʻonui i ka apoptosis ke hoʻohālikelike ʻia i nā lāʻau ʻelua wale nō, e hōʻike ana i ka pilina synergistic e like me ka mea i ʻike ʻia me ibrutinib a me venetoclax. ʻO kahi hoʻokolohua vivo ma hope e hōʻike i ka ola lōʻihi i nāʻiole i mālama ʻia me nā acalabrutinib a me nā venetoclax i hoʻohālikelike ʻia i nā lāʻau ʻelua wale nō.

 

(3) hopena a

I ka hōʻuluʻulu manaʻo, hōʻike ʻia nā noiʻi i hōʻike ʻia he hopena koʻikoʻi ka acalabrutinib i ka mālama ʻana iā CLL, nāifif a me nā refactory i hoʻi hou ʻia. ʻAʻole maopopo inā ʻoi aku ka maikaʻi a i ʻole ʻoi aku i ka ibrutinib a ke hoʻomau nei nā noiʻi i ka hoʻāʻo e hoʻohālikelike hou i kēia mau ʻākena. ʻOiai nā mea ʻona e pili ana i ka BTK e pili ana i ke kahe ʻana o ke kahe a i ʻole atrial fibrillation nā hanana pinepine ʻole, acalabrutinib loaʻa iā ia kahi hiʻohiona AE ʻokoʻa, ʻo ia hoʻi ka ʻeha o ke poʻo, kahi e koi ai i ka nānā pono ʻana a me ka mākaukau i ka hoʻokele. E kōkua ka ʻikepili mai ka hoʻomau ʻana i ka loiloi i nā hui pū me ka acalabrutinib e wehewehe hou aku i kāna kuleana i ka hoʻokele o CLL. ʻO ka mea hope loa, me ka ʻae ʻia o FDA, ʻo ka ʻike honua maoli me ka acalabrutinib e kōkua e wehewehe hou aku i ka ʻikepili ʻino.

ʻO AASraw ka mea hana ʻoihana o Acalabrutinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Reference

[1] ʻO US Food and Drug Administration. Papahana Orbis: ʻae ʻo FDA i ka acalabrutinib no CLL a me SLL. Loaʻa ma https://www.fda.gov/drugs/resource-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll. Loaʻa iā ʻApelila 29, 2020.

[2] Sharman JP, Banerji V, Fogliatto LM, et al. ʻO ELEVATE-TN: Ke aʻo ʻekolu o ka acalabrutinib i hui pū ʻia me ka obinutuzumab a i ʻole ʻo ia wale nō a me obinutuzumab a me chlorambucil i nā mea maʻi me ka leukemia lymphocytic mau maʻi maʻamau. ʻO ke koko 3; 2019 (suppl 134): 1.

[3] Hoʻolaha Press ʻo AstraZeneca. Ua ʻae ʻia ka Calquence i ka US no nā poʻe mākua me ka leukemia lymphocytic mau. Loaʻa ma https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. Loaʻa iā ʻApelila 29, 2020.

[4] Goede V, Fischer K, Busch R, et al. ʻO Obinutuzumab a me chlorambucil i nā mea maʻi me CLL a me nā ʻano noho like. N Engl J Med. 2014; 370 (12): 1101-1110. hana: 10.1056 / NEJMoa1313984.

[5] Parikh SA, Manytar E, Laplant B, et al. ʻO kahi papahana 2 i hoʻohālikelike ʻia e hoʻohālikelike ana i ka acalabrutinib me a i ʻole obinutuzumab i ka mālama ʻana i nā mea maʻi kiʻekiʻe loa me Chronic Lymphocytic Leukemia (CLL) a i ʻole Lymphocytic Lymphoma Liʻiliʻi (SLL). Koko. 2019; 134 (Pākuʻi_1): 4306. hana: 10.1182 / koko-2019-123824.

[6] ʻO Covey T, Gulranjani M, Cheung J, et al. ʻO ka loiloi Pharmacodynamic o acalabrutinib i nā mea maʻi i hoʻi hou ʻia / refactory a me nā lāʻau lapaʻau-naive me Chronic Lymphocytic Leukemia (CLL) i ke kaʻina 1/2 ACE-CL-001 Haʻawina. Koko. 2017; 130 (Pākuʻi1): 1741. hana: 10.1182 / koko.V130.Suppl_1.1741.1741.

[7] Byrd JC, Brown JR, O'Brien S, et al. ʻO Ibrutinib me ka ofatumumab i mālama mua ʻia i ka leukemia lymphoid mau. N Engl J Med. 2014; 371 (3): 213-223. hana: 10.1056 / NEJMoa1400376.

[8] ʻO Woyach JA, Bojnik E, Ruppert AS, et al. He mea nui ka hana a Bruton's tyrosine kinase (BTK) i ka hoʻomohala ʻana a me ka hoʻonui ʻana o ka leukemia lymphocytic mau (CLL). Koko. 2014; 123 (8): 1207-1213. hana: 10.1182 / koko-2013-07-515361.

[9] Chiorazzi N, Rai KR, Ferrarini M. Leukemia lymphocytic mau. N Engl J Med. 2005; 352 (8): 804-815. hana: 10.1056 / NEJMra041720.

[10] ʻO Barr PM, Robak T, Owen C, et al. Ka hoʻomau ʻana i ka pono a me ka ʻike kikoʻī e pili ana i ka hana mua ibrutinib i nā mea maʻi me ka leukemia lymphocytic maʻi mau: ua hoʻonui ʻia ka pae 3 mau hopena mai RESONATE-2. Haematologica. 2018; 103 (9): 1502-1510. hana: 10.3324 / haematol.2018.192328.

[11] Herman SEM, Montraveta A, Niemann CU, et al. ʻO ka Bruton Tyrosine Kinase (BTK) mea kāohi ACP-196 hōʻike i ka hana lapaʻau i loko o ʻelua iole hoʻohālikelike o ka leukemia lymphocytic mau. Koko. 2015; 126 (23): 2920. hana: 10.1182 / blood.V126.23.2920.2920.

 

 

1 Likes
2074 Views

E hiki no hoi i like

Comments ua paa.